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ABSTRACT		
Purpose	
To	report	on	cases	of	late	extraocular	relapse	of	previously	resected	iris	melanoma,	without	
concurrent	intraocular	recurrence.		
Design	
Retrospective	case	series.		
Methods	
A	retrospective	chart	review	of	4	patients	diagnosed	with	late	subconjunctival	relapse	of	
previously	resected	iris	melanoma.		
Results	
Three	females	and	one	male	underwent	iris	tumour	resection	and	presented	to	our	service	
with	suspicious	conjunctival	lesions	at	a	median	of	22	years	later	(mean:	21).	None	showed	
intraocular	relapse.	Treatment	of	the	conjunctival	tumours	included	excisional	biopsy	(n=4)	
followed	by	cryotherapy	(n=3)	and/or	brachytherapy	(n=3).	In	all	cases,	histopathology	
confirmed	malignant	melanoma,	with	no	intraepithelial	component	or	associated	melanosis.	
Genetic	sequencing	(n=3)	showed	wildtype	BRAF	and	NRAS	in	all.	GNA11	mutation	was	
found	in	1	case.	On	array	CGH	(n=3),	gain	of	6p	was	found	in	2	cases	and	gain	of	8	in	2.	
Overall,	findings	were	strongly	suggestive	of	a	diagnosis	of	late	extraocular	relapse	from	
previously	resected	iris	melanoma.	In	a	median	of	2.5	years	(mean:	7.7)	from	the	
subconjunctival	relapse,	no	further	episodes	of	intra/extraocular	recurrence	were	recorded,	
and	all	patients	were	free	from	distant	metastasis.		
Conclusions	
Patients	undergoing	iris	melanoma	resection	are	at	risk	of	developing	late	solitary	
extraocular	relapse	even	over	30	years	after	surgery.	In	the	absence	of	an	intraocular	
component,	diagnosis	may	be	challenging,	as	tumours	mimic	a	primary	conjunctival	lesion.	
Management	by	excisional	biopsy	followed	by	adjuvant	therapy	was	successful,	and	
histopathology	and	genetic	analysis	supported	a	diagnosis	of	extraocular	uveal	tumour	
spread	rather	than	a	primary	conjunctival	tumour.		
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INTRODUCTION	
Uveal	melanoma	is	a	rare	malignancy	and	iris	melanoma	is	the	rarest	variant,	accounting	for	
2-3%	of	cases.1,2	Compared	to	choroidal	and	ciliary	body	melanoma,	iris	melanoma	is	
associated	with	better	prognosis,	with	5%	of	patients	estimated	to	develop	metastasis	
within	10	years.1	Traditionally,	the	majority	of	iris	melanoma	cases	were	treated	by	tumour	
resection	or	enucleation.3–5	However,	enucleation	was	generally	abandoned	as	a	primary	
modality	for	this	indication,	reserved	only	for	cases	associated	with	a	circumferential	
drainage	angle	component	(“ring	melanoma”)	or	extraocular	extension,	and	tumour	
resection,	which	was	a	common	therapeutic	approach	in	the	second	half	of	the	20th	century,	
was	largely	replaced	at	the	turn	of	the	century	with	conservative	radiotherapy.6–12	Over	80%	
of	such	cases	are	now	treated	by	plaque	brachytherapy	or	proton	beam	radiotherapy,13	
especially	as	iris	melanoma	resection	requires	management	of	long-term	postoperative	
complications.14,15		
It	is	estimated	that	15%	of	uveal	melanoma	patients	develop	extraocular	tumour	
extension,16	also,	though	in	lower	rates,	from	iris	melanoma.1,17	When	extraocular	extension	
of	untreated	iris	melanoma	occurs	it	is	usually	continuous	with	the	intraocular	iris	mass.	In	
resected	cases,	the	recurrence	most	often	occurs	at	the	edge	of	the	surgical	margin.	Herein	
we	report	the	diagnosis	and	management	of	a	series	of	4	cases	of	late	solitary	extraocular	
iris	melanoma	recurrence	following	resection	up	to	several	decades	previously.	
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Summary	of	Cases	
The	study	was	approved	by	the	Moorfields	Eye	Hospital	institutional	review	board	
(reference	number:	16/036)	in	accordance	with	the	tenets	of	the	Declaration	of	Helsinki.	
The	cohort	included	3	females	and	1	male	patient.	The	median	age	at	which	the	original	iris	
tumour	was	treated	(elsewhere	in	3	cases)	by	means	of	resection	was	28	years	old	(mean:	
36,	range:	26-60;	Table	1).	The	median	interval	from	iris	tumour	resection	to	presentation	to	
our	service	with	a	suspicious	conjunctival	lesion	was	22	years	(mean:	21,	range:	3-36).		
Presentation	
Of	the	4	patients,	2	presented	to	our	service	with	a	suspicious	conjunctival	lesion	and	
history	of	a	previously	excised	iris	tumour	of	unknown	nature.	No	supporting	medical	
documents	were	available	in	these	2	cases.	Of	the	remaining	2,	one	patient	initially	
presented	to	our	service	with	an	iris	tumour,	underwent	surgical	resection	and	the	diagnosis	
was	iris	melanoma.	Three	years	after	initial	diagnosis	and	treatment	the	patient	presented	
with	a	suspicious	conjunctival	lesion.	The	final	patient	first	presented	to	our	service	with	an	
intraocular	iris	melanoma	relapse	following	resection	elsewhere	for	which	she	was	treated	
with	ruthenium	plaque	brachytherapy.	Two	years	after	plaque	brachytherapy	the	patient	
presented	with	a	suspicious	conjunctival	lesion	with	no	intraocular	component.		
Clinical	findings	and	management	
At	our	evaluation,	best-corrected	visual	acuity	of	the	involved	eye	at	presentation	with	the	
suspicious	conjunctival	lesion	was	20/20	in	2	cases,	20/30	in	another	and	light	perception	
(LP)	in	a	fourth	case,	and	median	intraocular	pressure	(IOP)	was	14mmHg	(mean:	13,	range:	
12-14).	Examination	of	the	suspicious	conjunctival	lesions	revealed	a	single	small	(<5mm	in	
diameter)	red	lesion	in	one	case,	large	single	multilobed	pink	lesion	in	another,	and	several	
small	pigmented	lesions	in	2	cases.	Lesions	in	all	cases	were	located	on	the	bulbar	
conjunctiva	on	the	side	of	the	resected	iris	in	the	same	quadrant	as	the	iris	melanoma.	A	
concurrent	intraocular	tumour	relapse	was	not	present	in	any	of	the	cases.	Surgical	
management	of	the	suspicious	conjunctival	lesions	included	excisional	biopsy	followed	by	
cryotherapy	in	3	cases	(2014-2016),	and	excisional	biopsy	only	in	one	case	(1991).		
Histopathology	and	genetic	studies	
Histopathology	of	the	conjunctival	specimens	revealed	all	cases	to	be	invasive	malignant	
melanoma,	with	no	intraepithelial	component	and	no	associated	melanosis	with	atypia.	
Three	cases	were	reported	to	be	incompletely	excised	at	the	deep	margin.	In	one	case	
(1991),	margin	involvement	was	not	indicated	(further	histopathologic	evaluation	was	not	
possible).	Of	the	4	cases,	samples	from	3	were	available	for	genetic	mutation	analysis	(Table	
2	and	Supplemental	Digital	Table	1),	including	GNAQ	and	GNA11,18,19	and	BRAF	and	NRAS.20	
The	latter	were	found	to	be	wildtype	in	all	cases	evaluated,	whereas	a	mutation	in	GNA11	
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Q209	was	found	in	a	single	case.	Further	array	CGH	analysis21,22	was	performed	on	the	3	
cases	(via	whole	genome	amplification	in	2	cases):	in	1	case	changes	were	not	detected,	in	
the	other	2,	altered	chromosomes	included	6p+	in	both,	8p	in	1	and	8p	and	8q	in	1.	Further	
genetic	analysis	findings	are	shown	in	Table	2.		
Adjuvant	therapy	and	outcome	
Three	patients	were	treated	with	adjuvant	strontium	radiotherapy,	one	declined.	In	a	
median	follow-up	of	2.5	years	(mean:	7.7,	range:	0.8-25.0)	from	presentation	with	the	
extraocular	relapse,	no	cases	of	intra-	or	extraocular	relapse	were	recorded.	Systemic	
surveillance	was	performed	by	an	expert	medical	oncologist,	radiographically	by	means	of	
abdominal	ultrasound	every	6	months,	and	all	were	found	to	be	free	from	distant	metastatic	
spread.			
Case	1		
A	43-year-old	white	female	was	referred	to	our	service	in	March	2011	due	to	spontaneous	
hyphaema	in	the	left	eye	associated	with	elevated	IOP	and	history	of	left	iris	melanoma	
resection,	performed	elsewhere	15	years	earlier.	Supporting	documents	confirmed	the	
primary	diagnosis	and	treatment,	indicating	there	was	no	postoperative	residual	mass.	On	
our	examination,	BCVA	was	20/30	in	each	eye.	The	right	eye	was	normal.	In	the	left	eye	
there	was	evidence	of	sector	iridectomy	temporally.	Inferonasally	was	an	intraocular	tan-
coloured	elevated	iris	mass	lesion	that	encompassed	2	clock	hours	(Fig.	1).	No	hyphaema	
was	present	and	IOP	was	17mmHg.	Gonioscopy	revealed	the	mass	was	reaching	the	iris	root	
but	was	not	spreading	circumferentially	into	the	angle,	and	showed	no	seeding	into	the	
angle.	Transpupillary	transillumination	failed	to	demonstrate	a	ciliary	body	component,	and	
fundus	examination	was	normal.	The	patient	underwent	ruthenium	plaque	radiotherapy	
(total	of	80Gy)	for	the	intraocular	relapse	and	on	follow-up	examinations,	the	tumour	had	
regressed,	no	iris	neovascularization	developed	and	IOP	remained	within	normal	limits.	Two	
years	after	brachytherapy,	the	patient	presented	with	a	red	4x4mm	lesion	in	the	supero-
temporal	aspect	of	the	left	bulbar	conjunctiva	with	an	associated	feeder	vessel.	BCVA	was	
20/30,	IOP	14mmHg	and	there	were	no	signs	of	intraocular	tumour	relapse	(ruled	out	by	
means	of	gonioscopy,	B-scan	ultrasonography	(US)	and	ultrasound	biomicroscopy	(UBM)).	
Topical	maxitrol	drops	did	not	resolve	the	lesion,	so	an	excisional	biopsy	was	undertaken.	
On	histopathology,	a	nodule	of	malignant	melanoma	comprising	epithelioid	cells	with	
moderate	pleomorphism	was	identified.	The	tumour	was	present	in	the	stroma,	without	
involvement	of	the	overlying	epithelium	and	was	incompletely	excised	at	the	deep	margin.	
There	was	no	evidence	of	melanosis	with	atypia.	Immunohistochemistry	was	positive	for	
Melan	A	and	HMB45	and	failed	to	demonstrate	an	intraepithelial	component.	Genetic	
sequencing	performed	on	DNA	extracted	from	the	extraocular	sample	found	BRAF	and	
NRAS	to	be	wildtype.	GNAQ	and	GNA11	were	also	found	to	be	wildtype.	On	array	CGH	
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analysis,	trisomy	6p	and	8p	were	found.	The	diagnosis	was	a	late	extraocular	relapse,	with	
no	intraocular	component,	of	a	previously	resected	iris	melanoma,	and	the	patient	was	
treated	with	adjuvant	strontium	radiotherapy	(total	of	50Gy).	During	follow-up,	no	intra-	or	
extraocular	relapses	were	recorded.	At	the	last	visit,	40	months	after	treatment	of	the	
extraocular	recurrence,	the	eye	was	tumour-free,	BCVA	was	counting	fingers,	IOP	26mmHg	
under	Cosopt	BID,	and	brunescent	cataract	was	present.	Systemically,	she	remains	free	from	
distant	metastatic	spread.		
	
Case	2		
An	87-year-old	white	male	patient	was	referred	to	our	service	in	November	2014	due	to	a	
large	pink	conjunctival	mass	in	the	left	eye,	that	he	first	noticed	8	months	earlier.	His	
medical	history	was	positive	for	a	basal	cell	carcinoma,	previously	excised	from	his	forehead,	
and,	per	patient	anamnesis,	a	left	iris	tumour	previously	excised	elsewhere	27	years	earlier.	
No	supporting	medical	documents	were	available.	On	examination,	BCVA	were	20/60	in	the	
right	eye	and	LP	in	the	left.	Anterior	and	posterior	segments	of	the	right	eye	were	
unremarkable,	but	nuclear	sclerosis	cataract.	The	left	eye	had	a	multilobed,	vascularized,	
non-pigmented	conjunctival	mass	lesion	at	the	infero-nasal	limbus,	encroaching	over	4	clock	
hours	(Fig.	2).	IOP	was	14	mmHg,	there	was	a	large	inferonasal	iris	defect	and	advanced	
cataract,	precluding	fundus	view.	Gonioscopy,	US,	UBM	and	anterior	chamber	optical	
coherence	tomography	(AC-OCT)	ruled	out	the	presence	of	an	intraocular	tumour,	and	
computed	tomography	failed	to	demonstrate	an	orbital	mass.	The	patient	refused	excisional	
biopsy,	hence	was	given	interferon	α-2b	eye	drops,	offered	as	a	conservative	alternative.	
Two	months	after	initial	topical	therapy	the	conjunctival	tumour	increased	in	size.	Excisional	
biopsy,	alcohol	epitheliectomy,	cryotherapy	and	placement	of	an	amniotic	membrane	graft	
were	performed.	On	histopathology,	a	large	nodule	of	malignant	melanoma	was	found,	
located	within	the	subepithelial	stroma,	with	no	junctional	component.	Morphology	was	
predominantly	spindle	cell,	with	minimal	melanin	pigmentation.	The	tumour	was	shown	to	
be	incompletely	excised	at	the	deep	surgical	margin,	and	there	was	no	evidence	for	
melanosis	with	atypia.	Immunohistochemistry	was	strongly	and	diffusely	positive	for	both	
Melan	A	and	HMB45,	and	AE1/AE3	confirmed	there	was	no	junctional	component.	On	
genetic	sequencing,	a	mutation	in	GNA11,	exon	5,	codon	209	was	found.	All	others	were	
wildtype.	On	array	CGH	analysis,	gain	of	6p,	and	trisomy	8	were	detected.	Given	the	
patient’s	history	and	laboratory	findings,	the	diagnosis	was	of	an	extraocular	relapse	of	an	
iris	melanoma	excised	many	years	earlier.	The	patient	declined	further	adjuvant	ocular	
treatments	and	on	last	follow-up	visit,	18	months	after	initial	presentation	to	our	service,	
BCVA	was	LP,	IOP	21mmHg,	the	conjunctiva	healed,	without	intra-	or	extraocular	relapse.	
Systemically	the	patient	was	clear	of	metastasis.		
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Case	3		
A	64-year-old	white	female	noticed	new	conjunctival	lesions	in	her	right	eye	and	was	
referred	in	April	2016	to	our	service	for	evaluation	and	management.	History	was	positive	
for	an	iris	tumour	resection	in	the	same	eye,	performed	elsewhere	36	years	earlier.	She	had	
no	supporting	medical	documents,	and	was	not	aware	of	the	precise	original	tissue	
diagnosis,	but	stated	that	it	was	a	cancer	excised	from	the	iris	during	pregnancy,	and	that	
she	has	been	clear	since.	General	medical	history	was	positive	only	for	sleep	apnoea.	On	
examination,	BCVA	was	20/20	in	each	eye.	The	left	eye	was	structurally	normal.	In	the	right	
eye	there	was	an	inferior	broad	iridectomy.	On	the	conjunctiva	there	were	3	discrete	
pigmented	spots	adjacent	to	the	original	area	of	corneal	incision	(Fig.	3).	Two	of	these	were	
mobile	and	one	appeared	to	be	deeper.	IOP	was	12mmHg,	gonioscopy	showed	normal	
ciliary	processes	with	no	other	ciliary	body	lesion,	and	US	and	AC-OCT	failed	to	demonstrate	
an	intraocular	lesion.	The	lesions	were	excised	with	adjuvant	cryotherapy	and	on	
histopathology,	all	specimens	showed	similar	features	–	fairly	well-demarcated	spindle	cell	
malignant	melanoma	with	modest	melanin	pigmentation.	Excision	was	incomplete	at	the	
deep	margin	in	all	3	specimens	and,	in	all;	the	conjunctival	surface	epithelium	was	not	
involved.	There	was	no	evidence	of	melanosis	with	atypia	and	immunohistochemistry	was	
strongly	positive	for	Melan	A,	with	modest	positivity	for	HMB45.	Additional	
immunohistochemistry	staining	for	CD34	delineated	an	apparent	structure	surrounding	the	
lesions,	raising	the	possibility	that	the	tumour	was	within	lymphatic	channels.	Further	
staining	however	with	D2-40	was	negative.	Genetic	sequencing	performed	on	DNA	
extracted	from	the	extraocular	sample	found	BRAF	and	NRAS	to	be	wildtype.	GNAQ	and	
GNA11	were	also	wildtype.	On	array	CGH	analysis,	no	changes	were	detected,	likely	due	to	
technical	difficulties	associated	with	the	small	size	of	the	lesion.	Taken	together,	the	
diagnosis	was	of	a	late	extraocular	relapse	of	a	previously	resected	iris	melanoma	and	the	
patient	was	further	treated	with	adjuvant	therapy	strontium	radiotherapy	(total	of	50Gy).	
On	last	follow-up	visit,	10	months	after	presentation,	BCVA	was	20/20,	IOP	13mmHg	and	no	
intra-	or	extraocular	relapse	was	noticed.	Systemically,	the	patient	remains	clear.		
	
Case	4		
A	28-year-old	white	woman	patient	was	referred	in	January	1988	with	an	iris	mass	in	the	
right	eye.	BCVA	was	20/20	in	both	eyes	and	examination	of	the	left	eye	was	unremarkable.	
Examination	of	the	right	eye	revealed	a	pigmented	iris	tumour,	occupying	the	inferonasal	
quadrant,	extending	from	the	angle	to	the	mid-pupillary	zone	and	anteriorly	to	the	cornea	
endothelium,	and	measuring	5x5	mm	(Fig.	4).	IOP	was	16	mmHg	and	fundoscopy	was	
normal.	The	patient	underwent	iridocyclectomy,	and	histopathology	indicated	that	the	
tumour	was	a	malignant	spindle	cell	melanoma.	On	follow-up	visit	in	January	1991,	the	
patient	presented	with	new	sub-conjunctival	pigmented	lesions	on	the	nasal	aspect	of	the	
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bulbar	conjunctiva,	but	with	no	intraocular	component	(ruled	out	by	means	of	gonioscopy	
and	US).	She	underwent	a	biopsy,	which	showed	spindle	melanoma	cells	arranged	in	solid	
coves	within	lymphatic	vessels.	The	working	diagnosis	was	late	extraocular	relapse	of	a	
previously	excised	iris	melanoma	and	the	patient	was	treated	with	adjuvant	strontium	
radiotherapy	(total	of	50Gy).	She	was	further	followed-up	for	25	years,	last	seen	in	August	
2016,	at	which	visit	BCVA	was	20/30,	IOP	17mmHg,	eye	tumour-free,	and	systemically	she	
was	free	from	metastasis.	
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DISCUSSION	
Melanoma	of	the	iris	is	a	relatively	rare	diagnosis	that	has	a	better	local	and	systemic	
prognosis	compared	to	ocular	melanoma	at	other	sites.	Treatments	used	have	included	
surgical	resection	and	radiotherapy	with	plaque	applicators	or	proton	beam.	Local	relapse	is	
encountered	infrequently,	and	if	it	occurs	tends	to	involve	the	margin	of	the	original	
tumour.		In	the	current	study,	we	report	the	previously	undocumented	finding	that	patients	
who	previously	underwent	iris	melanoma	resection	are	at	risk	of	developing	late	extraocular	
tumour	relapse	with	no	concurrent	intraocular	component.		
This	form	of	extraocular	recurrence	may	mimic	a	primary	conjunctival	tumour	and	
surprisingly	the	onset	can	be	decades	after	the	primary	iris	tumour	resection.	Surgical	
resection	has	largely	been	replaced	by	radiotherapy,13	but	there	are	many	patients	under	
long-term	follow	up	after	iridectomy	or	iridocyclectomy	for	melanoma,	so	recognition	of	
late	subconjunctival	relapse	is	of	the	utmost	importance	for	the	general	ophthalmologist,	
ocular	oncologist	and	pathologist.		
In	the	literature,	there	are	several	publications	on	surgical	resection	of	iris	tumours,	but	
none	have	reported	the	phenomenon	of	late	conjunctival	relapse	in	the	absence	of	
intraocular	disease.	Vail	reviewed	244	cases	of	iridocyclectomy	for	iris	and	ciliary	body	
tumours,	presumably	most	were	uveal	melanomas,	and	did	not	report	on	any	case	of	
extraocular	tumour	relapse.23	Similarly,	Reese	and	Cleasby	in	their	study	on	63	iris	
melanoma	cases	that	underwent	iridectomy,	did	not	encounter	this	complication.3	Rones	
and	Zimmerman	reported	on	125	iris	melanoma	cases	that	underwent	iridectomy.4	In	their	
series	they	described	3	cases	that	developed	extraocular	relapse,	but	which	also	had	a	
concurrent	intraocular	component.	Daubner	et	al.	monitored	20	iris	melanoma	cases	for	a	
mean	time	of	16.4	years	after	performing	iridocyclectomy	and	found	that	2	relapsed,	but	
only	intraocularly,14	and	no	case	of	extraocular	relapse	was	reported	in	a	review	by	Müller	
on	70	resected	iris	malignant	tumours	(presumably	most	were	uveal	melanoma).24	Shields	
et	al.	reported	on	169	iris	melanoma	patients,	102	of	which	were	treated	by	local	resection.1	
Patients	were	followed-up	for	a	mean	of	nearly	10	years,	at	which	time	no	case	of	
extraocular	extension	was	found.	Popovic	et	al.	recently	reviewed	the	literature,13	
comparing	iris	melanoma	management	outcomes	after	conservative	radiotherapy	versus	
surgical	resection.	The	recurrence	pattern	described	in	the	present	study	was	not	reported	
in	their	review,	which	included	relatively	recent	studies	(2001	and	on).	Altogether,	we	could	
not	find	in	the	literature	any	description	of	the	complication	herein	reported	of	late	
extraocular	subconjunctival	recurrence	from	previously	resected	iris	melanoma.		
From	a	diagnostic	perspective,	the	cases	shown	in	this	study	were	challenging,	first	at	
presentation,	when	only	clinical	data	was	at	hand,	and	differential	diagnosis	included	late	
relapse	of	a	previously	excised	presumed	iris	melanoma	versus	a	primary	conjunctival	
lesion,	and	second,	after	histopathology	assessment	indicated	the	lesions	were	invasive	
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melanoma,	to	differentiate	pathologically	between	the	aetiology	of	an	iris	(late	extraocular	
spread)	or	conjunctival	(new	primary)	tumour.	The	long	period	between	iris	surgery	and	
presentation	with	an	ocular	surface	lesion,	the	presence	of	an	ocular	surface	lesion	in	the	
absence	of	an	active	intraocular	recurrence,	and	the	lack	of	reports	in	the	literature	on	this	
clinical	entity,	have	led	us	in	2	of	the	cases	(#1	and	#2)	to	consider	other	possible	ocular	
surface	pathologies	as	the	initial	working	diagnosis.	Of	note,	in	2	cases,	lesions	were	
amelanotic,	in	case	#1,	in	contrast	to	a	previously	pigmented	intraocular	relapse.	However,	
all	subconjunctival	recurrences	occurred	in	the	same	quadrant	as	the	resected	iris	
melanoma.	
The	alternative	diagnosis	of	a	primary	iris	and	distinct	primary	conjunctival	melanoma,	has	
been	described	but	is	rare.25	In	this	regard,	histopathology	and	immunohistochemistry	were	
found	to	be	useful	diagnostic	tools,	ruling	out	the	presence	of	melanosis	with	atypia,	a	
common	predisposing	condition	for	the	development	of	primary	conjunctival	melanoma,	
and	in	showing	there	was	no	junctional	component,26	suggesting	that	tumour	origin	was	
from	a	previously	excised	iris	melanoma.		
To	further	characterize	the	lesions	and	strengthen	our	hypothesis	regarding	the	origin	of	the	
melanomas,	we	undertook	genetic	testing	using	sequencing	and	array	CGH	analyses	
techniques.	Interestingly,	BRAF	and	NRAS,	both	mutations	known	to	be	associated	with	
conjunctival	melanoma,27,28	were	found	to	be	wildtype,	likely	excluding	this	diagnosis.	In	
addition,	of	the	3	cases	tested	for	common	uveal	melanoma	mutations,18,19,22	GNA11	was	
found	in	1	case	as	well	as	partial	trisomy	6p	and	8q.	In	another	case	partial	trisomy	6p	was	
found.	A	third	case	was	wildtype	for	all	tested	genes	and	the	array	profile	was	flat,	most	likely	as	a	
result	of	contaminating	normal	tissue	and	the	small	size	of	the	lesion.	Taken	together,	genetic	
analysis	results	support	a	uveal	melanoma	origin	and	overall	a	diagnosis	of	late	extraocular	
relapse	of	a	previously	resected	iris	melanoma.		
In	terms	of	the	mechanism	of	developing	late	extraocular	spread	with	no	concurrent	
intraocular	component,	one	possibility	is	implantation	of	melanoma	cells	into	the	
conjunctiva	during	surgical	removal.	Another	is	circulating	melanoma	cells	in	the	anterior	
chamber	that	after	tumour	removal	have	lodged	into	the	surgical	site	and	grown	over	time.	
A	third	possibility	is	post-surgery	tumour	cell	migration	via	lymphatic	vessels.	Only	little	is	
known	regarding	intraocular	lymphatics,	but	accumulating	evidence	suggests	the	presence	
of	lymphatic	structures	in	the	eye.29	However,	in	case	#3,	despite	positive	staining	for	CD34,	
negative	staining	for	D2-40	likely	ruled	out	this	option,30	and	in	case	#4,	further	tissue	
sample	for	immunostaining	was	not	available,	precluding	a	definite	diagnosis.	Whilst	the	
Zimmerman	hypothesis31	for	enucleation	surgery	for	intraocular	melanomas	has	been	
abandoned,32	it	is	possible	that	resection	surgery	for	iris	melanoma	plays	a	role	in	
extraocular	(subconjunctival)	recurrence.		
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The	interval	from	iris	tumour	resection	to	presentation	with	an	extraocular	relapse	ranged	
widely,	3-36	years,	with	a	mean	time	of	21	years	(median:	22	years).	Of	note,	3	out	of	4	of	
the	extraocular	tumours	comprised	spindle	cell	melanoma,	which	are	less	aggressive	and	
grow	in	slower	rate	compared	to	epithelioid	cells.33	Interestingly,	a	single	case	of	epithelioid	
cell	melanoma	relapsed	17	years	after	iris	tumour	resection,	whereas	a	case	of	spindle	cell	
melanoma	relapsed	3	years	after	primary	resection.	In	comparison,	intraocular	recurrence	
after	iris	tumour	resection,	an	infrequent	event,	occurred	in	4	(8%)	cases	as	reported	by	
Conway	et	al.,	in	a	mean	time	of	3.25	years	(range:	1-7)	from	initial	surgery.34	Distant	
metastasis	from	iris	melanoma,	also	an	uncommon	event,	occurred	in	9	(5%)	cases	
according	to	Shields	et	al.,	at	a	mean	interval	of	5	years	(median<4	years).1	We	have	no	
explanation	to	the	significantly	longer	time	span	to	develop	late	subconjunctival	relapse	in	
the	present	case	series	as	compared	to	the	time	to	develop	intraocular	relapse	or	distant	
metastasis	in	the	abovementioned	studies.		
Management	of	extraocular	recurrence	by	excisional	biopsy	followed	by	adjuvant	therapy	
(cryotherapy	(n=3)	and	strontium	radiotherapy	(n=3))	was	an	efficient	approach	in	these	
cases.	After	an	average	of	nearly	8	years,	all	patients	were	tumour,	extraocular	and	distant	
metastasis	free.	Extraocular	spread	of	uveal	melanoma	was	found	to	correlate	with	
increased	mortality	from	metastasis.16	However,	in	the	present	study	it	did	not	predispose	
patients	to	develop	distant	systemic	spread,	findings	that	coincide	with	the	known	low	iris	
melanoma	metastasis	rate.1		
Limitations	of	the	study	include	its	retrospective	design	and	small	cohort	size.	In	terms	of	
ruling	out	an	intraocular	tumour	component	at	time	of	extraocular	presentation,	
investigations	were	tailored	to	the	clinical	features.	Supportive	tests	such	as	ultrasound	and	
UBM	were	completed	in	the	majority	of	cases	to	reasonably	rule	out	the	possibility	of	a	contiguous	
intraocular	recurrence.	
In	summary,	patients	that	underwent	previous	iris	melanoma	resection	are	at	risk	of	
developing	solitary	extraocular	(subconjunctival)	recurrence	even	over	30	years	after	
primary	surgery.	In	the	absence	of	a	concurrent	active	intraocular	component,	initial	
diagnosis	can	be	challenging,	as	lesions	mimic	a	primary	conjunctival	tumour.	General	
ophthalmologists	and	ocular	oncologists	should	be	aware	of	this	mode	of	presentation.	
Management	by	excisional	biopsy	followed	by	adjuvant	therapy	was	found	to	be	useful	in	
reaching	tumour	control	and	histopathology,	immunohistochemistry	and	genetic	analysis	
were	required	to	complete	the	diagnosis,	and	rule	out	a	new	primary	conjunctival	
melanoma.	This	report	highlights	the	need	for	long-term	follow-up	for	patients	that	
previously	underwent	iris	melanoma	resection.		
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FIGURE	LEGEND	
Figure	1.	Case	1.	A	43-year-old	female	with	an	iris	melanoma	relapse	(arrow)	15	years	after	
primary	iridectomy	(Top	left),	shown	on	gonioscopy	not	to	involve	the	iridocorneal	angle	
(Top	center	left).	Nine	months	following	ruthenium	plaque	brachytherapy	the	intraocular	
melanoma	completely	regressed	(Top	center	right).	Two	years	after	brachytherapy	and	17	
years	after	iridectomy,	a	red	lesion	was	noticed	on	the	temporal	bulbar	conjunctiva,	distant	
from	the	intraocular	relapse	site	(Top	right).	Following	excisional	biopsy,	histopathology	
showed	the	lesion	was	invasive	melanoma	without	involvement	of	the	overlying	epithelium	
(Bottom	left;	H&E),	and	immunohistochemistry	was	found	to	be	positive	for	Melan	A	
(Bottom	center	left)	and	HMB45	(Bottom	center	right).	Following	adjuvant	strontium	
radiotherapy,	after	40	months,	the	patient	was	tumour-free	(Bottom	right).	
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Figure	2.	Case	2.	An	87-year-old	male	with	a	pink	conjunctival	mass	in	the	left	eye,	27	years	
after	left	iris	tumour	resection	(Top	left).	Two	months	following	treatment	with	interferon	
α-2b	eye	drops	the	tumour	has	increased	in	size	(Top	center).	Following	excisional	biopsy,	
histopathology	showed	the	tumour	was	invasive	melanoma	without	involvement	of	the	
overlying	epithelium	(Top	right;	H&E),	and	immunohistochemistry	was	found	to	be	positive	
for	Melan	A	(Bottom	left),	HMB45	(Bottom	center	left),	and	AE1/AE3	(Bottom	center	right).	
The	patient	refused	adjuvant	therapy;	however	18	months	after	initial	presentation	to	our	
service,	no	intra-or	extraocular	relapses	were	recorded	(Bottom	right).	
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Figure	3.	Case	3.	A	64-year-old	female	with	pigmented	conjunctival	lesions	in	her	right	eye,	
36	years	following	right	iris	tumour	resection	(Top	left	and	center).	Following	excisional	
biopsy,	histopathology	showed	the	tumour	was	invasive	melanoma	without	involvement	of	
the	overlying	epithelium	(Top	right;	H&E),	and	immunohistochemistry	was	found	to	be	
positive	for	Melan	A	(Bottom	left),	HMB45	(Bottom	center	left),	and	CD34	(Bottom	center	
right).	Following	adjuvant	strontium	radiotherapy,	after	10	months,	the	patient	was	tumour-
free	(Bottom	right).	
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Figure	4.	Case	4.	A	28-year-old	female	presented	in	January	1988	with	an	iris	tumour	in	the	
right	eye	(Top	left	and	center;	original	illustrations	from	patient’s	medical	chart).	Following	
iridectomy,	histopathology	indicated	the	tumour	was	an	iris	melanoma	(Top	right;	H&E).	
Three	years	later,	the	patient	presented	with	new	sub-conjunctival	pigmented	lesions	
(Bottom	left;	original	illustration	from	patient’s	medical	chart)	and	underwent	tissue	biopsy.	
Histopathology	showed	the	tumour	was	invasive	melanoma	without	involvement	of	the	
overlying	epithelium	(Bottom	center;	H&E).	On	last	visit,	25	years	after	the	extraocular	
relapse,	the	patient	was	tumour-free	(Bottom	right).	
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	Table	1.	Summary	of	cases	of	late	solitary	extraocular	locoregional	recurrence	from	previously	resected	iris	melanoma.		
Case/sex/	
eye	
Intraocular	tumour	 Extraocular	lesion	 Outcome	
	 Age	of	diagnosis	and	
primary	iris	tumour	
resection	(years)	
Age	of	presentation	
(interval	from	iris	
tumour	resection)	
(years)	
Surgical	
management		
Histopathology	 Adjuvant	
treatment	
Local	tumour	
control	(years	
of	follow-up)	
Metastasis	
1/F/LE	 26*	 43	(17)	 Ex	Bx,	cryo	 Invasive	melanoma	with	
no	intraepithelial	
component	and	
incompletely	excised	
Strontium	
radiotherapy	
Yes	(3.3)	 No	
2/M/LE	 60*	 87	(27)	 Ex	Bx,	alcohol	
epitheliectomy,	
cryo,	amniotic	
membrane	graft	
Invasive	melanoma	with	
no	intraepithelial	
component	and	
incompletely	excised	
Patient	
declined**	
Yes	(1.5)	 No	
3/F/RE	 28*	 64	(36)	 Ex	Bx,	cryo	 Invasive	melanoma	with	
no	intraepithelial	
component	and	
incompletely	excised.	
Tumour	suspected	to	be	
within	lymphatic	channels	
Strontium	
radiotherapy	
Yes	(0.8)	 No	
4/F/RE	 28	 31	(3)	 Ex	Bx	 Invasive	melanoma	
within	lymphatic	vessels	
Strontium	
radiotherapy	
Yes	(25)	 No	
*	Iris	tumour	diagnosis	and	primary	treatment	performed	elsewhere.		
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**	Adjuvant	treatment:	cryotherapy	was	performed	after	the	tumour	was	excised,	but	the	patient	declined	further	treatment	with	strontium	
plaque.		
Ex	Bx	–	excisional	biopsy,	cryo	–	cryotherapy.		
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Table	2.	Genetic	analysis	of	cases	of	late	solitary	extraocular	locoregional	recurrence	from	
previously	resected	iris	melanoma.		
Case	 Sequencing	for	GNAQ		Q209,	GNA11	Q209,	BRAF	
V600e,	NRAS	G12,	NRAS	G13	and	NRAS	Q61	
Array	CGH	analysis	
1	 Wildtype	 Focal	deletion	1q,	focal	deletions	3p	
and	3q,	6p+/6q-,	8p+,focal	changes	
11p,	16q-,focal	gain	18p,+20	
2	 GNA11	Q209	mutation	
All	the	rest	were	wildtype	
6p+/6q-,	+8,+18,+19,+20	+22	
3	 Wildtype	 No	changes	detected*	
4	 NA	 NA	
*	Tumour	DNA	was	too	small.		
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Supplemental	Digital	Table	1.	Primers	for	GNAQ,	GNA11,	BRAF	and	NRAS	sequencing	
Gene	 Exon	 Codon	 Forward	Primer	Sequence	5'-3'	 Reverse	Primer	Sequence	5'-3'	 Reference	
GNAQ 5	 209	 AGAAGTAAGTTCACTCCATTCCC TTCCCTAAGTTTGTAAGTAGTGC Onken	et	al.	19	
GNA11 5	 209	 CGCTGTGTCCTTTCAGGATG CCTCGTTGTCCGACT Van	Raamsdonk	et	al.	18	
BRAF 15	 600	 TCATAATGCTTGCTCTGATAGGA GGCCAAAAATTTAATCAG Edwards	et	al.	20	
NRAS 2	 12	and	13	 CGGTGTTTTTGCGTTCTCTAGTC TCCGACAAGTGAGAGACAGGAT In-house	designed	primers	
NRAS 3	 61	 TTGAGGGACAAACCAGATAGGC CCTTCGCCTGTCCTCATGTATT In-house	designed	primers	
	
	
